SEC Form 4 · accession 0001140361-16-083088
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
Oct 17, 2016
Accepted (ET)
Oct 19, 2016 · 4:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 17, 2016 | M | 41,666 | $17.54 | A | 365,034 | D | |
| Common StockF1,F2 | Oct 17, 2016 | S | 41,666 | $84.3908 | D | 323,368 | D | |
| Common Stock | holding | — | — | — | 25,758 | I | Shares held by Bienaime Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy Common Stock)F1,F3 | $17.54 | Oct 17, 2016 | M | 41,666 | D | May 20, 2007 | Nov 19, 2016 | Common Stock | 41,666 | 41,670 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on August 17, 2015. Mr. Bienaime's former spouse will receive approximately 17% of the net proceeds from the shares sold in this transaction pursuant to a martial separation agreement between her and Mr. Bienaime.
- F2The price in column 4 is the weighted average price. The price actually received ranged from $82.365 to $85.42. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F3Reflects the number of stock options outstanding after the transaction from this specific stock option grant.